Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

D Hainsworth

Showing results (1-10 of 392) with videos related to

Pageof 40
Sort By:
Seminars in Oncology|February 14, 2002
Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trialJohn D Hainsworth
The Oncologist|October 21, 2000
Monoclonal antibody therapy in lymphoid malignanciesJ D Hainsworth
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1993
The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancerJ D Hainsworth
Seminars in Oncology|February 28, 2001
Rituximab as first-line systemic therapy for patients with low-grade lymphomaJ D Hainsworth
The Oncologist|October 13, 2004
Practical aspects of weekly docetaxel administration schedulesJohn D Hainsworth
Seminars in Surgical Oncology|May 1, 1993
Development of serotonin antagonists for the control of chemotherapy-induced emesisJ D Hainsworth
European Journal of Cancer Care|February 14, 1998
Mitoxantrone, 5-fluorouracil and high-dose leucovorin (NFL) in the treatment of metastatic breast cancer: randomized comparison to cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and attempts to improve efficacy by adding paclitaxelJ D Hainsworth
Arthritis Research & Therapy|June 8, 2004
Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritisJohn D Hainsworth
Drugs|March 11, 2000
Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issuesJ D Hainsworth
Seminars in Oncology|February 1, 2017
Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trialJohn D Hainsworth
Pageof 40

Showing results (1-10 of 392) with videos related to

Sort By:
Pageof 40
Seminars in Oncology|February 14, 2002
Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: interim follow-up of a multicenter phase II trialJohn D Hainsworth
The Oncologist|October 21, 2000
Monoclonal antibody therapy in lymphoid malignanciesJ D Hainsworth
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 1, 1993
The use of mitoxantrone, 5-fluorouracil and high-dose leucovorin in the treatment of advanced breast cancerJ D Hainsworth
Seminars in Oncology|February 28, 2001
Rituximab as first-line systemic therapy for patients with low-grade lymphomaJ D Hainsworth
The Oncologist|October 13, 2004
Practical aspects of weekly docetaxel administration schedulesJohn D Hainsworth
Seminars in Surgical Oncology|May 1, 1993
Development of serotonin antagonists for the control of chemotherapy-induced emesisJ D Hainsworth
European Journal of Cancer Care|February 14, 1998
Mitoxantrone, 5-fluorouracil and high-dose leucovorin (NFL) in the treatment of metastatic breast cancer: randomized comparison to cyclophosphamide, methotrexate and 5-fluorouracil (CMF) and attempts to improve efficacy by adding paclitaxelJ D Hainsworth
Arthritis Research & Therapy|June 8, 2004
Safety of rituximab in the treatment of B cell malignancies: implications for rheumatoid arthritisJohn D Hainsworth
Drugs|March 11, 2000
Extended-schedule oral etoposide in selected neoplasms and overview of administration and scheduling issuesJ D Hainsworth
Seminars in Oncology|February 1, 2017
Rituximab as first-line and maintenance therapy for patients with indolent non-Hodgkin's lymphoma: Interim follow-up of a multicenter phase II trialJohn D Hainsworth
Pageof 40